Robert Dawson
Family · Marion, INNPI 1588727895
Payments from drug & device makers
Across 139 payments — averaging $15.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$824
- Gilead$204
- Axsome Therapeutics, Inc.$192
- Vanda Pharmaceuticals Inc.$173
- Novo Nordisk$123
- Otsuka America Pharmaceutical, Inc.$122
- plus $554 from 15 others
What the payments were for
- Food & beverage$2,04893%
- Education$1427%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 59 | $824 |
| Gilead | 11 | $204 |
| Axsome Therapeutics, Inc. | 7 | $192 |
| Vanda Pharmaceuticals Inc. | 15 | $173 |
| Novo Nordisk | 8 | $123 |
| Otsuka America Pharmaceutical, Inc. | 7 | $122 |
| Bayer | 6 | $101 |
| Lilly USA, LLC | 5 | $91 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $75 |
| AstraZeneca | 3 | $66 |
| Sunovion Pharmaceuticals Inc. | 2 | $41 |
| Dexcom, Inc. | 2 | $32 |
| GSK | 2 | $29 |
| Alkermes, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Amgen | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Organon | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $11 |
| Corium, LLC | 1 | $6 |
How this compares
$2,190 in reported general payments places this provider in the 80th percentile of 4,392 family providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 132 | $143,257 |
| JardianceEmpagliflozin | 62 | $50,493 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 64 | $45,440 |
| XifaxanRifaximin | 11 | $35,366 |
| MounjaroTirzepatide | 27 | $29,407 |
| EliquisApixaban | 16 | $21,918 |
| RexultiBrexpiprazole | 13 | $18,870 |
| EntrestoSacubitril/Valsartan | 19 | $15,506 |
| TradjentaLinagliptin | 17 | $13,788 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $12,300 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $9,465 |
| Levemir FlexpenInsulin Detemir | 33 | $8,194 |
| JanuviaSitagliptin Phosphate | 14 | $7,696 |
| Humalog Kwikpen U-100Insulin Lispro | 27 | $6,607 |
| MyrbetriqMirabegron | 12 | $5,378 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $123 | $143,257132 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $29 | $67,205107 claims |
| Lilly USA, LLCMounjaro | $91 | $29,40727 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $122 | $18,87013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,392 family providers in Indiana.
Other family in Marion
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.